Preparation of [68Ga]PSMA-11 for PET-CT imaging using a manual synthesis module and organic matrix based 68Ge/68Ga generator

Nuclear Medicine and Biology

Volumn 43, Issue 8, 2016, Pages 463-469

  Nanabala, Raviteja ^a   Anees, Muhammed K ^a   Sasikumar, Arun ^a   Joy, Ajith ^a   Pillai, M R A ^b  

^a KIMS DDNMRC   (India)

^b Molecular Group of Companies   (India)

Author keywords

68Ga PSMA 11; 68Ge 68Ga generator; PET CT imaging; Prostate cancer; PSMA inhibitor; Radiolabeling

Indexed keywords

ACETIC ACID; GALLIUM 68; GERMANIUM; GERMANIUM 68; PROSTATE MEMBRANE SPECIFIC ANTIGEN 11 GA 68; TRACER; UNCLASSIFIED DRUG; (68GA)GLU-UREA-LYS(AHX)-HBED-CC; GALLIUM; ORGANOMETALLIC COMPOUND;

ABSENCE OF SIDE EFFECTS; ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DRUG PURITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; RADIOACTIVITY; RADIOCHEMISTRY; CHEMISTRY; DRUG STABILITY; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PROCEDURES; QUALITY CONTROL; SYNTHESIS;

CHEMISTRY TECHNIQUES, SYNTHETIC; DRUG STABILITY; GALLIUM RADIOISOTOPES; GERMANIUM; ORGANOMETALLIC COMPOUNDS; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; QUALITY CONTROL; RADIOCHEMISTRY;

EID: 84969932809     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2016.05.006     Document Type: Article

References (38)

1. World Cancer Research Foundation [Accessed on 30.3.2015]. http://www.wcrf.org/int/cancer-facts-figures/worldwide-data.
2. Jadvar H Molecular imaging of prostate cancer: PET radiotracers. AJR Am J Roentgenol 2012, 199:278-291.
3. 68Ga-PMSA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med 2015, 56:668-674.
4. 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2015, 42:197-209.
5. 68Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer. Eur J Nucl Med Mol Imaging 2016, 43:70-83.
6. Prata MIM Gallium-68: a new trend in PET radiopharmacy. Curr Radiopharm 2012, 5:142-149.
7. Roesch F Maturation of a key resource - the germanium-68/gallium-68 generator: development and new insights. Curr Radiopharm 2012, 5:202-211.
8. Knapp FF, Pillai MRA, Osso JA, Dash A Re-emergence of the important role of radionuclide generators to provide diagnostic and therapeutic radionuclides to meet future research and clinical demands. J Radioanal Nucl Chem 2014, 302:1053-1068.
9. 68Ga generators. Nucl Med Biol 2016, 43:19-26.
10. Pinto JT, Suffoletto BP, Berzin TM, et al. Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res 1996, 2:1445-1451.
11. Ghosh A, Wang X, Klein E, Heston WD Novel role of prostate-specific membrane antigen in suppressing prostate cancer invasiveness. Cancer Res 2005, 65:727-731.
12. Zhou J, Neale JH, Pomper MG, et al. NAAG peptidase inhibitors and their potential potency for diagnosis and therapy. Nat Rev Drug Discov 2005, 4:1015-1026.
13. Kiess AP, Banerjee SR, Mease RC, Rowe SP, Rao A, Foss CA, et al. Prostate-specific membrane antigen as a target for cancer imaging and therapy. Q J Nucl Med Mol Imaging 2015, 59:241-268.
14. Kozikowski AP, Nan F, Conti P, Zhang J, Ramadan E, Bzdega T, et al. Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase). J Med Chem 2001, 44:298-301.
15. Foss CA, Mease RC, Fan H, et al. Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Clin Cancer Res 2005, 11:4022-4028.
16. 68Ga-complexes lipophilicity and the targeting property of a urea-based PMSA inhibitor for pet imaging. Bioconjug Chem 2012, 23:688-687.
17. 68Ga]Ga-PSMA-HBED-CC: a new PET tracer for imaging of prostate cancer. Pharmaceutics 2014, 7:779-796.
18. Luetje S, Heskamp S, Cornelissen AS, et al. PMSA ligands for radionuclide imaging and therapy of prostate cancer: clinical status. Theranostics 2015, 5:1388-1401.
19. Sasikumar A, Joy A, Nanabala R, Pillai MRA, Thomas B, Vikrman KR 68Ga-PSMA PET-CT imaging primary hepatocellular cancer. Eur J Nucl Med Imaging 2016, 45:795-796.
20. http://www.itg-garching.de/2016-02-29-09-31-17/product-platform/11-products/42-iqs-ga-68-fluidic-labeling-module.html.
21. Sodee DB, Malguria N, Faulhaber P, et al. Multi-center ProstaScint® imaging findings in 2154 patients with prostate cancer. The ProstaScint imaging centers. Urology 2000, 56:988-993.
22. 11C-MCG: synthesis, uptake selectivity, and primate PET of a probe for glutamate carboxypeptidase II (NAALADase). Mol Imaging 2002, 2:96-101.
23. Ghosh A, Wang X, Klein E, Heston WD Novel role of prostate-specific membrane antigen in suppressing prostate cancer invasiveness. Cancer Res 2005, 65(3):727-731.
24. 18F-DCFBC PET/CT for PSMA-based detection and characterization of primary prostate cancer. J Nucl Med 2015, 56:1003-1010.
25. 18F PET/CT. Clin Genitourin Cancer 2016, 14:115-118.
26. 68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. J Med Chem 2010, 53:5333-5341.
27. Weineisen M, Simecek J, Schottelius M, et al. Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer. Eur J Nucl Med Mol Imaging Res 2014, 4(1):63.
28. Gourni E, Canovas C, Goncalves V, et al. (R)-NODAGA-PSMA: a versatile precursor for radiometal labeling and nuclear imaging of PSMA-positive tumors. PLoS One 2015, 10(12):e0145755.
29. Martell AE, Motekaitis RJ, Clarke ET, Harisson JJ Synthesis of N,N'-di(2-hydroxybenzyl)ethylenediamine,N-N'-diacetic acid (HBED) and derivatives. Can J Chem 1986, 64:449-456.
30. Pillai MRA, Lo JM, John CS, Schlemper EO, Troutner DE μ-oxo-bis-oxo complexes of Tc(V) with amine phenol ligands: synthesis, characterization, and X-ray crystal structures. Inorg Chem 1990, 29:1850-1856.
31. inuclear complexes of Re(V) with amine-phenol ligands. Syntheses, characterization and X-ray crystal structures. Polyhedron 1994, 13:701-708.
32. 105Rh] rhodium using a pentadentate bifunctional ligand 1990, 1:191-197.
33. Zöller M, Schuhmacher J, Reed J, Maier-Borst W, Matzku S Establishment and characterization of monoclonal antibodies against an octahedral Ga-chelate suitable for immunoscintigraphy with PET. J Nucl Med 1992, 33:1366-1372.
34. Kubícek V, Havlícková J, Kotek J, Tircsó G, Hermann P, Tóth E, et al. Gallium(III) complexes of DOTA and DOTA-monoamide: kinetic and thermodynamic studies. Inorg Chem 2010, 49:10960-10969.
35. Barinka C, Rojas C, Slusher B, Pomper M Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer. Curr Med Chem 2012, 19:856-870.
36. 68Ga-PET imaging of prostate cancer. EJNMMI Research 2012, 2:23.
37. 68Ga-DKFZ-PSMA-11 and its performance in prostate cancer patients. Molecules 2015, 20:14860-14878.
38. ation of its clinical efficacy. Mol Imaging Biol 2016, 16. [Epub ahead of print PubMed PMID: 26983703].